Abstract
In atopic dermatitis (AD), Th2 cytokines, including interleukin (IL)-13, alter skin lipid metabolism. Tralokinumab is a high-affinity, monoclonal antibody that neutralizes IL-13. We evaluated effects of tralokinumab on stratum corneum (SC) lipid composition in adolescents with moderate-to-severe AD (ECZTRA 6, NCT03526861). Adolescents (age 12-17) were randomized to subcutaneous tralokinumab 150mg, 300mg every 2 weeks, or placebo. Primary endpoints were IGA 0/1 and EASI-75 at Week 16. Tape strip samples were collected for SC lipid and transcriptomics analyses in lesional and non-lesional skin while ceramides, sphingomyelins and natural moisturizing factor (NMF) components were quantified using targeted LC-ESI-MS/MS.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
